RNF8 and pachyonychia congenita: Silencing RNF8 further reduces AR/ARV7 transactivation and PSA expression in enzalutamide-resistant PC cells treated with enzalutamide (Figs. 4G, H, 5E, F and Supplementary Fig. 6D).